Lastly, we demonstrate the therapeutic potential of miR–129-5p since systemic delivery of miR–129-5p mimic in an AngII HF model was able to attenuate the further progression of preexisting cardiac hypertrophy, myocardial fibrosis, and calcification marker expression; it was also able to restore systolic and diastolic function that was dysregulated by AngII. The gene discussed is AGT; the disease is cardiac hypertrophy.